InsidersTradesSigma
Track the PHARMANUTRA PHARMANUTRA - PHN: THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2025 stock price and the full management transaction log of the company, a listed issuer based in Italy. Shares trade on the IT market, under the oversight of Consob. Operating in the Health Care sector, PHARMANUTRA PHARMANUTRA - PHN: THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2025 has published 0 public disclosures. Market capitalisation: €799.5m. The full history is free.
n/a
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Fundamental score
Ranked 8,636 of 29,064 companies
61.7
score / 100
Value39
Quality85
FCF yld2.1%
Earn yld2.5%
EV/EBITDA23.9x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Declarations0 total
No declarations found
0 of 0 declarations
About PHARMANUTRA PHARMANUTRA - PHN: THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2025
PHARMANUTRA is a company operating in the health and pharmaceutical sector. The board of directors approved the draft financial statements and the consolidated financial statements as of December 31, 2025.